Concepedia

Lindsey Rolfe

LR

Statistics

Publications

23

Citations

3.8K

H-Index

16

Active since

2000

Affiliations

Clovis Oncology (United States)(Current)

Institut Gustave Roussy

Massachusetts General Hospital

University of California, Los Angeles

The University of Texas MD Anderson Cancer Center

Lindsey Rolfe is an author at Clovis Oncology (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

2000–2018

23

Publications

23

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

, , +12

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman et al. · New England Journal of Medicine · 2015 · 664 citations · Full text

, , +14

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Karen L. Reckamp, Vladislava O. Melnikova, Chris Karlovich et al. · Journal of Thoracic Oncology · 2016 · 285 citations · Full text

, , +17

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Amit M. Oza, Anna V. Tinker, Ana Oaknin et al. · Gynecologic Oncology · 2017 · 278 citations · Full text

, , +17

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris et al. · Clinical Cancer Research · 2017 · 236 citations

, , +16

1–5 of 23